Media headlines about Agios Pharmaceuticals (NASDAQ:AGIO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Agios Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 43.9858593605549 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) opened at 70.25 on Thursday. The company has a 50 day moving average of $63.02 and a 200 day moving average of $55.90. Agios Pharmaceuticals has a 52 week low of $39.24 and a 52 week high of $71.40. The firm’s market cap is $3.40 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. During the same period in the previous year, the company posted ($1.47) earnings per share. Agios Pharmaceuticals’s revenue was up 62.1% compared to the same quarter last year. On average, equities research analysts anticipate that Agios Pharmaceuticals will post ($7.07) EPS for the current fiscal year.

Several brokerages have issued reports on AGIO. SunTrust Banks, Inc. reissued a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $83.00 price objective (up from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. J P Morgan Chase & Co reissued a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Royal Bank Of Canada began coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective on the stock. Finally, Cann reissued a “buy” rating and set a $75.00 price objective on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $75.20.

TRADEMARK VIOLATION NOTICE: “Agios Pharmaceuticals (AGIO) Receives Coverage Optimism Score of 0.16” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/agios-pharmaceuticals-agio-receives-coverage-optimism-score-of-0-16/1608996.html.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 35,000 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $67.12, for a total transaction of $2,349,200.00. Following the completion of the sale, the chief executive officer now directly owns 35,000 shares of the company’s stock, valued at $2,349,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Scott Biller sold 2,146 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $67.23, for a total transaction of $144,275.58. The disclosure for this sale can be found here. Insiders have sold 140,084 shares of company stock valued at $8,750,408 over the last ninety days. Insiders own 10.55% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.